(CercleFinance.com) – Abivax announces the presentation of four scientific abstracts on its main drug candidate, obefazimod, in moderately to severely active ulcerative colitis (UC) and in a preclinical model of colon cancer.
“These new preclinical data show the impact of obefazimod on reducing tumor numbers in the azoxymethane/dextran sulfate sodium salt mouse model of inflammation-associated cancer,” says Medical Director Sheldon Sloan.
The abstracts will be presented during the Digestive Disease Week (DDW) conference, which will be held from May 18 to 21 in Washington, providing the biotechnology company with the opportunity to continue its discussions with the community of experts in this field.